24 Feb. 2021

BioVersys, TASK and GSK receive 2.7 million Euro from EDCTP for Phase 2a Clinical Trial

BioVersys and consortium partners TASK Foundation and GSK have been awarded 2.7 million Euro from European and Developing Countries Trial Partnership...


12 Jan. 2021

BioVersys reports first dosing of BVL-GSK098 in clinical Phase I

BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a grea...


18 Nov. 2020

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100

Today marks the start of the World Antimicrobial Awareness Week 2020 by the WHO, underlining once more the incredibly important health emergency that...


01 Sep. 2020

BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candid...